Estimates from the American Heart Association (I) suggest that approximately one million Americans are hospitalized each year as a result of acute myocardial infarction. Over the past several years, clinical management of many of these patients has undergone radical change, with increased use of thlombolytic drugs, such as streptokinase and recombinant tissue-type plasminogen activator (r&PA) (2-9). as well as aggressive use of coronary angioplasty and bypass surgery on either an emergent or urgent basis (IO.1 I). Recent clinical trials (12) suggest that thrombolytic therapy might reduce the in-hospital mortality rate of patients with acute myocardial infarction by as much as 50%. In contrast to the tremendous attention being paid worldwide to the evaluation of the comparative efficacy of alternative therapies for myocardial infarction, relatively little attention has been paid to either their comparative cost-effectiveness or the capacity of our current health care system to provide alternative therapies on a large scale basis. One exception is the recent analysis performed by Laffel et al. (13) . which estimated, from society's perspective, the relative cost-effectiveness of four primary treatments for acute infarction and three strategies for the prevention of reocclusion. In that analysis (13) . the estimated increased cost per additional survivor compared with standard therapy ranged from $12,000 for treatment of a large infarction with intravenous streptokinase within 2 h of the onset of symptoms to $1.8 million for treatment of a small infarction within 4 h of the onset of symptoms with intravenous r&PA plus coronary artery bypass surgery. Methods Structure OF d&ion model: treatmcat stratcgks. For each of the seven treatment strategies, we developed a clinical management algorithm t'krbtree") that reflected pertinent diagnostic and therapeutic oprions and outcomes. These treatment strategy subtrees formed the basis of our decision analysis model. Our subtree for the conventional treatment strategy is shown in Figure I . For ctinventionally treated patients, we assumed that I) all patients with recurrent ischemic myocardial pain would undergo cardiac catheterization, followed by coronary angioplasty, bypass surgery or medical treatment, depending on catheterization results; 2) some but not all patients without recurrent ischemic myocardial pain would undergo predischarge exercise electrocardiographic (EC@ testing: 3) patients with a nep tive exercise test would be managed medically, whereas Flgurc 2. Clincat management algorithm (subtree) for emergency and 48 h catheterization treatment strategies. SK = streptokinese: IPA = recombinant tissue-type plasminogen activator: other abbreviations as in Figure I .
patients with a positive exercise test would undergo catheterization. followed by coronary angioplasty or bypass surgery or medical treatment, depending on catheterization results; and 4) some but not all patients in whom attempted coronary angioplasty was unsuccessful would be referred for bypass surgery. Our conventional treatment strategy is consistent with the management strategy recently considered to be the most cost-effective for asymptomatic postinfarction patients by the Cardiovascular Norms Committee of the American College of Cardiology (14).
Tke SIFIICIII~~ of ortr srdmw jbr tire siteptokinusr und r&PA rredrrtrenr srrutegirs was the same as for conventional treatment cxccpt for inclusion of the possibility that thrombolytic drug treatment might result in a bleeding complication that was either fatal or severe enough to preclude the use of other diagnostic or therapeutic procedures in the management of myocardial infarction. . In these strategies, we assumed that the suusequent management of all patients who did clot suffer severe bleeding complications would be de:srmined by the coronary anatomy visualized at catheterization.
Data sources: clinical variables. We used three different sources of information to develop best, high and low estimales for each clinical variable in our medcl. First. we performed a detailed review of studies published through the end of Gi. We used published data to estimate clinical variables whenever such data were available, Second, to obtain estimates for what we expected to be key variables for which published data were htcking, we sent a questionnaire in late t98b to IS cardiologists--S who were universitybased and involved in thrombolysis research, 5 who were university-based, but not involved in thrombolysis research and 5 who were nonuniversity-based and in private practice. By .A.pri! 1987, we received responses from 13 (87%) of these cardiologists (see Acknowledgments). We calculated the mean, median, trimmed mean (the mean after excluding the highest and lowest response) and Winsorized mean (the mean after replacing the highest and lowest responses with the next highest and next lowest responses) response for each variable addressed in our questionnaire. Because there was little difference in the vaiues derived from these different measures of ces!ral tendency, we used the ordinary mean as our best estimah~. We used the 75th and 25th percentile responses as our high and low estimates, respectively, of each variable estimated from our questionnaire responses. Finally, for variables for which we had no other data source, we used the consensus estimate of the two cardiologists on our research team (E.J.T. and A.D.G.).
Assumptions: clinical variables. The best, high and low estimates that we employed for each clinical variable in our model, as well as the sources used for each estimate, are available from the authors upon written request. The key clinical assumptions that we employed are summarized in Table I and in the following discussion.
Mortality rates. We assumed an in-hospital mortality rate of I I .3% for conventional treatment (25.8) and 10.0% for treatment with streptokinase. The latter estimate was derived by taking a weighted average of the mortality rate experienced by streptokinase-treated patients who presented at 0 lo 3 and 3 to 6 h after the onset of symptoms in the Gruppo Italian0 per lo Studio della Streptochinasi nell'lnfarto Miocardico (GISSI) trial (2). Because we lacked empiric data regarding the mortality rate associated with treatment with rt-PA, we derived an estimate for it by assuming that the probability of surviving acute myocardial infarction is a linear function of the probability of infarctrelated artery patency immediately after initial treatment. Assuming that the probability of patency after initial treatment is 15% for conventional treatment (IS), 54% for strep tokinase (2,10,16-27) and 75% for r&PA (10.25-27). we interpolated an estimate of the in-hospital mortality rate with rt-PA treatment of 9.3%. We further assumed !ha! use of either emergency or 48 h catheterization on a routine basis in combination with streptokinase or rt-PA neither increased nor decreased patient mortality compared with the use of streptokinase or rt-PA alone (IO.1 I).
Bleeding complications. We assumed that the probability of a major central nervous system hemorrhage was 0.2% with streptokinase (2,5,9) and 0.4% with r&PA (24). We further assumed that 50% of patients with a major central nervous system hemorrhage would die (5, 23) and that the other 50% would not be considered candidates for coronary angioplasty o: bypass surgery.
PosthSa&on angina. Our estimates of the incidence of postinfarction angina were derived from our survey of n:,.liologists and the published studies (2.8,283. Survey responses reflected a belief that postinfarction angina would occur more commonly with streptokinase than with conventional treatment, and more commonly after treatment with II-PA than with streptokinase. Presumably this belief was based on an assumption that there would be a higher vessel patency rate with rt-PA than with streptokinase and that it would be higher with stleptokinase than with conventional therapy and that this higher patency rate would be associated with a reduced likelihood of completed infarction and an increased likelihood of subtotal stenoses and -esidual ischemic pain.
Exerrix ele&-acardbgraphy. Our estimates of the proportion of patients without postinfarction angina who would undergo ECG exercise testing and the percent uf those patie,lts who wruld have a positive exercise test (C&at is, a :cs; result ihat was sutiiciintly abnormal to prompt cardiac catheterization) 'were both derived from oer survey. Survey responses reflected the beliefs that the proportion of .Mients who would be able to undergo ECG exercise testing rnd the proportion of patients undergoing such testing whcs would have :1 positive test result wouid be higher with streptokinase than with conventional treatment and would be higher with r&PA than with streptokinase treatment. This belief presumably was based on reasoning similar to that described earlier.
Cardii cathcter*ptioa. We assumed that ail patients with postinfarction angina and all patients with a positive ECG exercise test would undergo catheterization. On the basis of a recent review of published reports (221 and the opinions of our cardiologist coinvestigators, we assumed that 0.5% of patients with postinfarction angina who underwent catheterization and 0.1% of patients without postinfarction angina who underwent catheterization would die as a result of the catheterization.
Coronary a ty vemia coronary artery bypass snrgery versus me&al tmtmeat. Our estimates of the frequency with which patients would be treated with angiob2A STEINBERG ET AL. plasty or bypass surgery versus medical treatment alone under treatment strategies I to 3 were derived from our survey of cardiologists, and under treatment strategies 4 to 7, these estimates were derived from the published reports and our cardiologist coinvcstigators. We assumed that a slightly higher proportion of patients would undergo bypass surgery if cathc*erization were routinely performed at 48 h rather than on an emergency basis because of the additional time physicians would have to reflect about optimal treatmen:. Our assumed tab: for rt-PA treatment is slightly higher than that for streprokinase treatment because of a presump tion that severe left ventricular dys unction would be present less frequently after rt-PA than .!fter streptokinase treatment. We also assumed that the probability that there would be no need for either angioplasty or bypass surgery would bc higher in patients treated with rt-PA than in those treated with streptokinase (as a result of the higher assumed thrombolytic efficacy of r&PA) and would be higher for both treatments when catheterization was performed at 48 h rather than on an emergency basis (as a result of a higher patency rate at 48 h). Coronary nngloplasty. We assumed that 0. I% of patients undergoing angioplasty would have a fatal complication (16.29) , that an additional 3% would have a complication that required emergency bypass surgery (20. [29] [30] [31] [32] and that 8% of the latter would die during bypass surgery (l&30,33-353. In addition, we assumed a 90% success rate for angioplasty performed on patent vessels, an 85% success rate for angioplasty performed on vessels that remained occluded after conventional treatment or treatment with streptokinase and a 75% success rate for angioplasty performed on vessels that remained occluded after treatment with t-t-PA (26.36,37) . Our assumption that tine angioplasiy success rate is Ivwcr for vessels that remain occluded after r&PA treatment is based 'n our cardiologist coinvcstigators' experience that such vessels are more resistant to balloon angioplasty. We also assumed that patients with ~JStinfRrctiOR angina were more likely to have a patent infarct-related artery than were patients without postinfarction angina and that 80% of patients in whom angioplasty was unsuccessful would undergo bypass surgery.
Coronary artery bypass surgery. We assumed an operative mortality rate of 7% for patients with postinfarction angina undergoing hypass surgery (17, 19, 21, 38, 39) . 2% for patients without postinfarction angina undergoing bypass surgery (w3) and 8% for patients undergoing emergency bypass surgery as result of an angioplasty-related complication (18.30.33-35) .
Bats sources and assumptions: costs. We estimated hospital payment rates by assuming that all procedures would be performed during the initial hospitalization for myocardial infarction and then assigning to each subtree branch the Diagnosis-Related Group (DRG) that Medicare would assign to patients managed according to that branch, For example, Table I. because they underwent coronary angioplasty, patients managed according to the top branch of the conventional treatment strategy subtree would be assigned to DRG II2 (vascular procedures except major reconstruction). The five DRGs that we considered for patients hospitalized for acute myocardial infarction and the corresponding fiscal year 1988 Medicare hospital payment rates for Baltimore metropolitan area hospitals that we employed for them (44) are listed in Table A of the Appendix.
We estimated the professional fees associated with each sub/fee branch by assuming I) a $190 fee for a comprehensive admission history and physical examination, 2) a $55 fee for each subsequent day of daily care, 3) the length of a patient's hospital stay was the arithmetic mean length of stay for the DRG to which they were assigned, and 4) physicians' professional fees for cardiac catheterization, coronary angioplasty and bypass surgery as shown in Table B of the Appendix.
We did not consider either the cost of thrombolytic drugs or the potential effect cf thrombolytic treatment on patients' lengths of stay in our cost estimates because neither of these factors allects current Medicare payment rates.
Sensitivity analyses. The sensitivity of our results to the assumptions we employed was examined in both univariate and multivariate sensitivity analyses. In these analyses, we varied the estimated value of each variable across a range determined by our high and low estimates for that variable. All computations were performed using an IBM PC-AT nticrocornptuer supporting a decision analysis software program (SMLTREE) and a spreadsheet (LOTUS t-2-3).
Results
Total costs. 'Assumes a mortality rate of I I .3% for conventional treatment. IO 0% for streptokinase (SKI strategies and 9.3 .Z fc: n-PA stmte~er. Abbrevlatmns as in Table I. suggests that, on average, ireatment with streptokinase is approximately $700 more cosdy to Medicare than conventional treatment, whereas treatment with r&PA is approximately $450 more costly than treatment with streptokinase, even without considering the cost CI thrombolytic drugs themselves. The expected cost to Medicare of each of thr four emergency and 48 h catheterization strategies is approximately $4,000 greater than that of conventional treatment.
Cod per life saved. Our baseline assumptions regarding the mortalhy rate associated with each of the seven treatment strategies imply that, for every I.000 patients treated. all three streptokinase strategies would result in an additional I3 lives saved compared with conventional treatment, whereas all three r&PA strategies would result in an additional 20 lives saved compared with conventional treatment. On the basis of our estimates of the costs for each treatmem strategy (Table 2) . Figure 3 . Sensitivity of estimates of cost per case and procedure volumes to simultaneous variation in the estimates for three <aria-bles: probability of postinfarction angina, probability of undergoing exercise tolerance testing and Probability of exercise tolerance test results being positive. Rest = model projection using our best estimate for each of the three variables simultaneously; conventional = conventional treatment; high = model projection using our highest estimate for each of the three variables simultaneously; low = model projection using our lowest estimate for each of the three variables simultaneously; SK = intravenous streptokinase; TPA = intravenous recombinant tissue-type plasminogen actiwtor.
than for streptokinase, regardless of the exact estimate for each of these three variables. Relaxation of this assumption narrows the differences between strategies in the estimates of the cost per case and procedure volumes (analysis not shown). Because DRG payment rates for patients with acute myocardidl infarction vary depending on whether bypass surgery, angioplasty or medical treatment alone is prcvided, our estimates of the cost per case for each of the seven treatment strategies vary as our estimate of the proportion of patients undergoing either bypass surgery or angioplasty changes. So, too, of course, does our estimate of the number of each !ype of procedure performed under each of the seven treatment strategies (Table 5 ). The estimated cost to Medicare per patient treated can be nearly $1,898 higher in institutions that aggressively provide bypass surgery compared with those that tend to perform bypass surgery on patients less aggressively. Table 5 also demonstrates the marked variation in the frequency zvith which coronary angioplasty and bypass surgery could be provided under any given treatment strategy.
Finally, becaase recent data (12) suggest that mortality rates associated with thrombolytic treatment may be lower than those we employed in our primary analyses, we explored the sensitivity of our major dependent variables, (cost per case, cost-effectiveness and procedure volumes) to assumed mortality rates. A comparison of results assuming an rt-PA treatment mortality rate of 5 versus 9.3% (Table 6) illustrates the effect of our mortality rate assumption. This analysis demonstrates that neither estimated cost per case nor estimated volume of cardiac catheterizations, angioplasty procedures or bypass operations changes considerably over a broad range of mortality rates. In contrast, the estimated cost per additional life saved with thrombolytic therapy compared with conventional treatment decreases substantially as the mortality rate associated with thrombolytic treatment decreases.
Discussion
The efficacy of thrombolyiic iherapy in reducing the mortality rate from acute myocardial infarction has generated extraordinary excitement within the medical profession and the public at large. As the medical profession focuses its efforts on defining which of the currently available treatment alternatives is the most efficacious and on the development of new treatment strategies, attention must also be given to the costs of alternative !rtarment strategies and to the facilities that would be required to perform the cardiac catheterizations, angioplasty procedures and bypass operations that would likely be generated by alternative treatment strategies. Cesfs per case. Our analysis suggests that when costs are estimated from the perspective of Medicare, treatment strategies involving the use of either streptokinase or r&PA alone, even though they are more expensive ihan conventional traalment, result in additional lives being saved at a cost that IS reasonably low and compares favorably with the increased cost per additional life saved associated with other common medical practices, such as renal dialysis ($54,000 [I983 dollars] per quality adjusted life year gained) (45) and treatment of a cholesterol level of 315 mg/dl in men ~50 years of age ($56,000 to $69,OtNJ [1987 dollars] per year of lift gained) (46) . In contrast, routine performance of emergency or 48 h cardiac catheterization in combination with use of streptokinase or rt-PA is considerably more expensive. Given our assumptior that the use of emergency 48 h catheterization on a routine basis does not improve the short-term survival rate, these strategies are also less costeffective than the use of streptokinase or &PA alone.
It is important to emphasize that our cost estimates reflect expected CC~?P to Medicarc under the current DRG-based prospective payment system, rather than actual resource costs incurred by hospital providers or society. Our analysis demonstrates that under this payment system, the costs to Medicare of alternative strategies for treatment of acute myocardial infarction are determined by the extent to which each treatment alternative shifts patients out of DRGs explicitly established for patients with myocardial infarction (DRGs 121, 122 and 123) and into higher paying DRGs associated with performance of bypdss surgery (DRG 106) or angioplasty (DRG 112). Our model's suggestion that treatment with &PA is more costly to Medicare than is treatment with streptokinase is thus due to a series of assumptions *hat result in a higher projected rate of angioplasty and bypass surgery after treatment with r&PA compared with streptokinase. These assmnptions reflect beliefs that r&PA has a higher thrombolytic efficacy than streptokinase, which, in turn, will reduce mortality but inrrease the proportion of patients with residual ischemia. Simdarly, our model's suggestion that 48 h catheterization strategies are more expensive than emergency catheterization strategies is a result of our assumption that more patients will undergo bypass surgery if treatment decisions are based on the results of catheterization performed at 48 h rather than on an emergency basis as a result of the additional time physicians would have to reflect on optimal treatment. Additional experience is required to know whether, in fact, such assumptions are valid. Over the longer term, DRG payment rates will be adjusted to reflect not only the cost of thrombolytic drugs, but also the effect of thrombolytic drugs on patients' lengths of stay and resource use during hospitalization. Even without an explicit decision by Medicare to adjust DRC payment rates, Medicare could become liable for the cost of thrombolytic drugs under certain circumstances. For example, if it were feasible and safe to administer thrombolytic drugs in an ambulance on route to the hospital, under current payment rules, the cost 6: thtontbolytic drugs would be ccvered under Part B of Medicare, and hence would be paid outside of the DRG system. (Part B of Medicare covers professional fees and cell&t other services.) The cost of thrombolytic drugs is also curently paid for under Part B of Medicare when the drugs are admk;steted in the emergency room of a hospital to a patient who is subsequently transferred to another hospital, rather than being admitted to the hospital that administers the drug. Whether ivieoicare wil! continue to pay for thrombolytic drugs under this circumstance is unclear.
Despite our use of considerably different methodologies, our cost estimates and conclusions arc remarkably consistent with those of another recently published analysis (13) of the cost-effectiveness of thrombolytic therapy for acute myocardial infarction. Whereas Laffel et al. (13) estimated the cost-effectiveness of alternative treatment strategies within numerous patient subgroups (for example, patients .with a small versus moderate versus a large infarction who presented within 2 versus 4 versus 6 h of the onset of symptoms) from the perspective of society, we developed estimates of the average mortality rates and costs associated with alternative treatment strategies based on the results of published clinical trials. Our assumption of an 11.3% mortality rate for conventional treatment corresponds roughly to the I?% in-hospital mortality rate Laffel et al. (13) assumed for patirots Wit!! a modera:c-sized ii&i&n.
Our estimates of approximately $53,000 and $57,tlOtl for the incremental cost per additional life saved for treatment with etreptokinase and rt-PA, respectively, compared with conventional treatment are comparable to the estimates of Laffel et al. (13) of $59,009 and %65,0&l for the marginal cost per additional life saved for treatment of a moderate-sized myocardial infarction within 2 h after the onset of symptoms with intravenous streptokinase aad iotravenous r&PA, respectively, compared with conventional treatment. In addition, Our estimates of the incremenlal cost per addiiiondl life saved for streptokinase or rt.PA in combination with emergency catheterization ($311,462 and $198.9CtO, respectively) are similar to those of Laffet et al. 113) of the marginal cost-effectiveness of similar strategies performed on patients presenting within 4 h of the onset of symptoms ($268,000 and $235.000, respectively).
Aggregate costs. The overall impact of thromholytic therapy on the costs of treatment of patients with acute myocardial infarction will depend on the number of patients who receive thrombolytic treatment. If one estimates, as the Prospective Payment Assessment Commission (unpublished data) has, that approximately 275,000 Medicare beneficiaries are hospitalized each year for acute myocardial infarction, it is likely that no more than 100,000 Medicare beneficiaries would receive thrombolytic therapy annually given current inclinations not to give thrombolytic drugs to most patients who are 275 years of age or who have a non-Q wave infarction (2&t). If tOO,OtlO Medicare heneticiaries were to be eligible for thromholytic therapy each year, then our model suggests that the use of streptokinase would increase Medicare costs by $70 million per year, whereas the use of +PA would increase Medicare costs by $114 million per year. Emergency and 48 h catheterization strategies would increase the cost to Medicare of treating 100,000 beneficiaries by $285 million to $350 million pr year.
Procedure vohmte. Our analysis atso suggests that thromholytic therapy wtii markedly increase the volume of cardiac catheterizations, coronary angioplasty procedures and coronary artery bypass operations that are performed in this country. Industry analysts have estimated that 175,BOtl coronary angioplasty procedures are performed each year in the United States (49) . and that the number of patients that would be considered eligible for thrombolytic treatment in the United States could he as high as 300,000 per year (50) . Our model suggests that treatment of 300,000 patients with acute myocardial infarction annually with rt-PA rather than conventional treatment would increase the annual number of coronary angioplasty procedures performed in the United States by 36.600 (21%), ignoring any effect of the use of rt-PA on the use of coronary angioplasty during the first or subsequent years after initial treatment for infarctions. Were facilities avaihtble to provide them, treatment of 3OO.OOtJ patients with streptokinase plus routine use of emergency cardiac catheterization would increase the annual volume of coronary angioplasty procedures by 159,000 (91% of the total number of coronary angioplasty procedures currently performed annually in the United States).
Limitations of study. Two important limitations of our analysis should be underscored. First, sensitivity analyses demonstrated that our conclusions regarding the costs per case and orocedure volumes are most sensitive to variables in our model, the values of which were estimated from our survey of cardiologists, rather than from published clinical studies. Our analysis of low and high as wel! as best estimates for these variables in our sensitivity analyses lessens the impact of this limitation by providing reasonable ranges for our estimates of outcome variables of interest. Our analysis demonstrates, however, that the impact of thrombolytic therapy on the frequency with which patients develop postinfarction angina and manifest a positive ECG exercise test will be an important determinant of the cost and procedure volume implications of thrombolytic therapy. Empiric data regarding these phenomena should, therefore, be collected.
Finally, in our malysis, we assessed both costs and outcomes from a short-term rather than a long-term perspective. Although recent data (5132) suggest that the decrease in the in-hospital mortality rate achievable with thrombolytic therapy is maintained over the year after acute myocardial infarction, additional research is needed to clarify the amount and types of resources consumed over an extended period by patients treated under alternative strategies. Ultimately, conclusions regarding the relative costs, procedure volume implications ar 7st-effectiveness of alternative treatment strategies should be based more on these longterm than on short-term outcomes.
